Abstract
This report describes the synthesis, characterization and biological activity of a series of platinum(IV) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)] (Pt56MeSS) with non-bioactive, lipophilic and bioactive axial ligands. In an attempt to explore the anticancer activity potential of the Pt(IV) derivatives, 2D and 3D cytotoxic screening and a preliminary in vivo study were performed. The average IC50 values of the platinum(IV) derivatives ranged from 1.26 to 5.39 mu M, compared with 1.24 mu M for Pt56MeSS, suggesting that the axial ligands have a relatively minor effect on the potency of the compounds. Preliminary in vivo studies indicate that the platinum(IV) derivatives of Pt56MeSS are active in vivo and can reduce the tumor to a similar extent to cisplatin.
| Original language | English |
|---|---|
| Pages (from-to) | 7005-7019 |
| Number of pages | 15 |
| Journal | Dalton Transactions |
| Volume | 46 |
| Issue number | 21 |
| DOIs | |
| Publication status | Published - 2017 |
Keywords
- Platinum complexes
- Drug development
- Cancer-cells
- Cytotoxicity
- Ligands
- Prodrugs
- Agents
- Metallointercalators
- Oxaliplatin
- Chemistry